Retinal Vein Occlusion: Two Common Injections Performed Similarly in a Review of Head-to-Head Trials

A retinal vein occlusion is a blockage in one of the veins that drain blood from the retina. It can cause fluid to build up in the macula, the center of sharp vision, a problem called macular edema. The first-line treatment is a series of injections of anti-VEGF medicine into the eye. Two widely used options are ranibizumab and bevacizumab, and patients often ask whether one is better. A meta-analysis published in BMC Ophthalmology looked only at trials that compared the two directly.

What the researchers did

Researchers in Guangdong, China, searched PubMed, Embase, the Cochrane Library, and Web of Science through February 2026. They included only randomized controlled trials that compared ranibizumab and bevacizumab head to head, each used alone, in adults with macular edema from a retinal vein occlusion. Four trials with 759 participants qualified.

What they found

• At 6 months, vision gains were similar between the two drugs, with an average difference of less than one letter on the eye chart.
• Changes in retinal thickness were also similar.
• The share of eyes gaining 15 or more letters (about three lines) was comparable.
• Safety profiles were broadly similar. Rare whole-body events were uncommon, and the evidence about them was very uncertain.

The authors rated the certainty of the evidence as moderate for vision outcomes and low to very low for rare side effects. Their conclusion: the two drugs show comparable short-term effectiveness and safety for this condition.

What this means for patients

For many people, the choice between these medicines depends on factors such as insurance coverage, cost, how the eye responds over time, and the retina specialist’s experience. This review covers only six months and only these two drugs, so it does not address newer medicines or long-term results.

Warning signs and next steps

• Sudden blurring or a dark area in the vision of one eye needs prompt evaluation.
• Vein occlusions are linked to high blood pressure, diabetes, high cholesterol, and glaucoma, so your primary care doctor is part of the team.
• If you are receiving injections, keep your visits; fluid can return between treatments.

Retinal vein occlusion is treated by retina specialists; ask your eye doctor for a referral if you have been diagnosed. For more plain-language reading on eye health, see los-angeles-lasik.com.

Source: Direct randomized evidence comparing ranibizumab and bevacizumab for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis (BMC Ophthalmology (PubMed), 07/30/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.